Anthem Biosciences Limited (BOM:544449)

Market Cap	409.75B
Revenue (ttm)	18.50B
Net Income (ttm)	4.51B
Shares Out	n/a
EPS (ttm)	8.04
PE Ratio	90.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,377
Average Volume	633,163
Open	746.75
Previous Close	750.45
Day's Range	725.00 - 755.00
52-Week Range	701.75 - 801.75
Beta	n/a
RSI	44.91
Earnings Date	n/a

About Splunk

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial...

• Industry: Industrial Inorganic Chemicals, not elsewhere classified
• Founded: 2006
• Employees: 1,825
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544449

Financial Performance

In 2024, Anthem Biosciences's revenue was 18.50 billion, an increase of 30.29% compared to the previous year's 14.20 billion. Earnings were 4.51 billion, an increase of 22.86%.